These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35988032)

  • 21. Pirfenidone mitigates TGF-β1-mediated fibrosis in an idiopathic inflammatory myositis-associated interstitial lung disease model.
    Layoun H; Hajal J; Saliba Y; Smayra V; Habr B; Fares N
    Cytokine; 2022 Jun; 154():155899. PubMed ID: 35504143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progression prediction in idiopathic inflammatory myopathy-associated interstitial lung disease: a combination of initial high attenuation areas and anti-melanoma differentiation-associated gene 5-positive.
    Fang X; Zou L; Zhao H; Liu B
    Clin Exp Rheumatol; 2024 Feb; 42(2):253-261. PubMed ID: 38293996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serological risk factors for concomitant interstitial lung disease in patients with idiopathic inflammatory myopathy.
    Huang HL; Lin WC; Yeh CC; Sun YT
    J Clin Neurosci; 2020 Apr; 74():32-35. PubMed ID: 31982271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: A Systematic Review.
    Teel A; Lu J; Park J; Singh N; Basharat P
    Semin Arthritis Rheum; 2022 Dec; 57():152088. PubMed ID: 36116345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of primary graft dysfunction following lung transplantation in selected adults with connective tissue disease-associated interstitial lung disease.
    Natalini JG; Diamond JM; Porteous MK; Lederer DJ; Wille KM; Weinacker AB; Orens JB; Shah PD; Lama VN; McDyer JF; Snyder LD; Hage CA; Singer JP; Ware LB; Cantu E; Oyster M; Kalman L; Christie JD; Kawut SM; Bernstein EJ
    J Heart Lung Transplant; 2021 May; 40(5):351-358. PubMed ID: 33637413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group.
    Trallero-Araguás E; Grau-Junyent JM; Labirua-Iturburu A; García-Hernández FJ; Monteagudo-Jiménez M; Fraile-Rodriguez G; Les-Bujanda I; Rodriguez-Carballeira M; Sáez-Comet L; Selva-O'Callaghan A;
    Semin Arthritis Rheum; 2016 Oct; 46(2):225-231. PubMed ID: 27139168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18F-FDG PET/CT and HRCT: a combined tool for risk stratification in idiopathic inflammatory myopathy-associated interstitial lung disease.
    Zhang Y; Chen Z; Long Y; Zhang B; He Q; Tang K; Zhang X
    Clin Rheumatol; 2022 Oct; 41(10):3095-3105. PubMed ID: 35759126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis.
    Barba T; Fort R; Cottin V; Provencher S; Durieu I; Jardel S; Hot A; Reynaud Q; Lega JC
    Autoimmun Rev; 2019 Feb; 18(2):113-122. PubMed ID: 30572131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of tacrolimus on top of glucocorticoids in the management of IIM-ILD: A retrospective and prospective study.
    Chen Y; Bai Z; Zhang Z; Hu Q; Zhong J; Dong L
    Front Immunol; 2022; 13():978429. PubMed ID: 36119045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease.
    Gui X; Shenyun S; Ding H; Wang R; Tong J; Yu M; Zhao T; Ma M; Ding J; Xin X; Qiu Y; Qiu X; Zhang Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
    Rheumatology (Oxford); 2022 Nov; 61(11):4570-4578. PubMed ID: 35148366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of natural killer cell depletion in predicting progressive fibrosing interstitial lung disease in idiopathic inflammatory myopathies.
    Shao C; Xia N; Zhen Y; Zhang X; Yan N; Guo Q
    Front Immunol; 2024; 15():1404828. PubMed ID: 38745647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors and Mortality of Rapidly Progressive Interstitial Lung Disease in Patients With Idiopathic Inflammatory Myopathy: A Series of 474 Patients.
    Li Y; Gao X; Li Y; Jia X; Zhang X; Xu Y; Gan Y; Li S; Chen R; He J; Sun X
    Front Med (Lausanne); 2020; 7():363. PubMed ID: 32850886
    [No Abstract]   [Full Text] [Related]  

  • 33. Dermatomyositis and Polymyositis in the Intensive Care Unit: A Single-Center Retrospective Cohort Study of 102 Patients.
    Peng JM; Du B; Wang Q; Weng L; Hu XY; Wu CY; Shi Y
    PLoS One; 2016; 11(4):e0154441. PubMed ID: 27115138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic plasma exchange for steroid refractory idiopathic inflammatory myopathies with interstitial lung disease.
    Thompson TZ; Bobr A; Juskewitch JE; Winters JL
    J Clin Apher; 2023 Aug; 38(4):481-490. PubMed ID: 36408807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory myositis-associated interstitial lung disease can be distinguished from that associated with other connective tissue diseases.
    Nurmi HM; Elfving PK; Kettunen HP; Suoranta SK; Järvinen HMI; Kuittinen VAE; Purokivi MK; Kaarteenaho RL; Koskela HO
    J Thorac Dis; 2023 Feb; 15(2):311-322. PubMed ID: 36910053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. hsa-miR-7 Is a Potential Biomarker for Idiopathic Inflammatory Myopathies with Interstitial Lung Disease in Humans.
    Yu L; Li J; Chen Y; Jiang J; Fang Q; Jiang J; Wang D; Liu M
    Ann Clin Lab Sci; 2018 Nov; 48(6):764-769. PubMed ID: 30610047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of Interstitial Lung Disease in Patients With Myositis Specific Autoantibodies.
    Mecoli CA; Christopher-Stine L
    Curr Rheumatol Rep; 2018 Apr; 20(5):27. PubMed ID: 29637383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mortality factors in idiopathic inflammatory myopathy: focusing on malignancy and interstitial lung disease.
    Woo JH; Kim YJ; Kim JJ; Choi CB; Sung YK; Kim TH; Jun JB; Bae SC; Yoo DH
    Mod Rheumatol; 2013 May; 23(3):503-8. PubMed ID: 22669599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of pulmonary and small airways function between idiopathic inflammatory myopathies patients with and without interstitial lung disease.
    Panagopoulos PK; Georgakopoulou VE; Pezoulas VC; Malagari K; Fotiadis DI; Goules AV; Vassilakopoulos T; Tzioufas AG
    Clin Exp Rheumatol; 2024 Feb; 42(2):337-343. PubMed ID: 37382448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zanubrutinib ameliorates experimental idiopathic inflammatory myopathy-associated interstitial lung disease by BTK/NF-κB signaling pathway.
    Liu Z; Liu Z; Li W; Yang Z; Meng L; Zhang T; Chai D; Liu J; Liu Y; Jiao R; Ai X; Li X; Zhou H
    Int Immunopharmacol; 2024 Dec; 143(Pt 1):113313. PubMed ID: 39388891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.